Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» sickle cell disease
sickle cell disease
Medicaid, with planned payment pilot, girds for influx of pricey gene therapies
BioPharma Dive
Tue, 02/21/23 - 04:37 pm
Medicaid
sickle cell disease
gene therapies
Bluebird Bio
Vertex Pharmaceuticals
CRISPR Therapeutics
Vertex Teases Launch of Landmark CRISPR Therapy
BioSpace
Thu, 02/9/23 - 10:45 am
Vertex Pharmaceuticals
exa-cel
sickle cell disease
CRISPR
Novartis' approved sickle cell disease drug fails to beat placebo in PhIII
Endpoints
Sun, 01/29/23 - 01:23 pm
Novartis
sickle cell disease
Adakveo
clinical trials
EMA validates Vertex's CRISPR application, clearing barrier on road to landmark approval
Fierce Biotech
Thu, 01/26/23 - 10:53 am
Vertex Pharmaceuticals
CRISPR Therapeutics
EMA
CRISPR
sickle cell disease
exa-cel
Graphite's hopes for sickle cell 'cure' blunted after first patient dosed experiences serious event
Fierce Biotech
Fri, 01/6/23 - 09:52 am
Graphite Bio
sickle cell disease
We finally have new drugs for sickle cell disease. Why are so few patients taking them?
Stat
Mon, 12/19/22 - 11:13 am
sickle cell disease
patients
Global Blood Therapeutics
Oxbryta
FDA Lifts Partial Clinical Hold On Bluebird Bio's Sickle Cell Disease Studies
NASDAQ
Mon, 12/19/22 - 10:59 am
Bluebird Bio
FDA
clinical trials
lovo-cel
sickle cell disease
ASH: Despite partial clinical hold, bluebird's sickle cell gene therapy remains on track
Fierce Pharma
Sun, 12/11/22 - 01:34 pm
Bluebird Bio
ASH 2022
Zynteglo
sickle cell disease
gene therapy
lovo-cel
Editas teases tiny sickle cell sample in effort to climb back into gene editing's upper echelon
Fierce Biotech
Tue, 12/6/22 - 10:34 am
Editas Medicine
sickle cell disease
gene editing
EDT-301
ASH preview – waiting for Editas
EP Vantage
Wed, 11/9/22 - 10:40 am
ASH 2022
sickle cell disease
Bluebird Bio
Sangamo BioSciences
Novartis
Editas Medicine
gene therapy
Vertex Pharmaceuticals
Sanofi
Vertex given green light to seek US approval of CRISPR-based therapy
BioPharma Dive
Wed, 09/28/22 - 12:01 am
Vertex Pharmaceuticals
CRISPR
CRISPR Therapeutics
FDA
exa-cel
beta thalassemia
sickle cell disease
Pfizer buys sickle cell drugmaker Global Blood for $5.4B
BioPharma Dive
Mon, 08/8/22 - 10:29 am
Pfizer
Global Blood Therapeutics
M&A
sickle cell disease
Oxbryta
Editas treats first patient in sickle cell trial as FDA lifts partial hold
BioPharma Dive
Fri, 07/29/22 - 10:03 am
Editas Medicine
clinical trials
CRISPR
gene editing
sickle cell disease
Editas’ Novel Sickle Cell Therapeutic Shows Early Promise
BioSpace
Wed, 07/27/22 - 06:39 pm
Editas Medicine
clinical trials
EDIT-301
sickle cell disease
Why Global Blood Therapeutics Trended Upward Today
Motley Fool
Wed, 06/29/22 - 05:32 pm
Global Blood Therapeutics
clinical trials
GBT601
sickle cell disease
Novartis plots Precision attack on sickle cell, paying $75M and putting up $1.4B in biobucks to form in vivo gene editing pact
Fierce Biotech
Wed, 06/22/22 - 10:23 am
Novartis
gene editing
Precision Biosciences
sickle cell disease
beta thalassemia
Imara to reduce staff by 83% amid biotech shakeout
BioPharma Dive
Mon, 04/18/22 - 10:50 am
Imara
layoffs
tovinontrine
beta thalassemia
sickle cell disease
Vertex’s Robust Pipeline is Ramping Up for Another Big Year
BioSpace
Wed, 04/13/22 - 10:35 am
Vertex Pharmaceuticals
cystic fibrosis
sickle cell disease
type 1 diabetes
Imara’s two trial flops in blood disorders dim drug’s prospects in heart failure
MedCity News
Wed, 04/6/22 - 12:21 pm
Imara
clinical trials
blood disorders
tovinontrine
sickle cell disease
beta thalassemia
A big year for sickle cell
EP Vantage
Tue, 03/1/22 - 10:12 am
sickle cell disease
Agios
mitapivat
CRISPR Therapeutics
CTX001
clinical trials
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
next ›
last »